Valeant Pharmaceuticals International
Worldwide Headquarters
One Enterprise
Aliso Viejo
California
92656
United States
Tel: 800-548-5100 or 949-461-6000
Fax: 714-556-0131
Website: http://www.valeant.com/
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.YEAR FOUNDED:
1960
LEADERSHIP:
CEO: Joseph C. Papa
CMO: Tage Ramakrishna
CFO: Robert Rosiello
CLINICAL TRIAL:
Please click here for clinical trial information.
JOB OPPORTUNITY:
Please click here for Valeant job opportunities.
953 articles about Valeant Pharmaceuticals International
-
Sanpower Group Completes The Acquisition Of Dendreon From Valeant
6/29/2017
-
Valeant Appoints Arthur J. Shannon As Senior Vice President, Head Of Investor Relations And Communications
6/20/2017
-
Valeant: Was iNova Pharma Sale The Worst Deal Ever?
6/19/2017
-
Valeant Surges As Its Largest Shareholder Joins Board
6/19/2017
-
The Not-So-Subtle Reason Behind Valeant' 30% Rise In May
6/8/2017
-
Debt-Laden Valeant Unloads iNova Pharma In $930 Million Deal
6/8/2017
-
Debt-Ridden Valeant Nears Sale of Its $2 Billion Eye Care Biz Bausch & Lomb
6/7/2017
-
68 Hedge Funds Buy Valeant For The First Time
5/31/2017
-
Why Valeant CEO Thinks Johnson & Johnson Should Foot The Bill For Their Talc Defense
5/25/2017
-
EyeGate Pharma Receives Milestone Payment From Valeant For EGP-437 For Post-Operative Ocular Inflammation And Pain In Ocular Surgery Patients
5/22/2017
-
Short Seller Who Unraveled Valeant Zeroes in On This Massachusetts Biotech
5/18/2017
-
Valeant Release: Statement Regarding Xifaxan Intellectual Property Litigation
5/17/2017
-
Is This The Real Reason Valeant's Shares Are Skyrocketing?
5/12/2017
-
Valeant Announces First Quarter 2017 Results And Raises Full Year Adjusted EBITDA Guidance Range
5/9/2017
-
Valeant Announces Key Appointments In Dermatology And Corporate Communications Leadership
5/8/2017
-
Valeant Management Tells The Future, If You Care To Listen
5/5/2017
-
Embattled Valeant Mulls Over Name Change For A Fresh Start
5/3/2017
-
Valeant Announces Additional Debt Reduction Of Approximately $220 Million
5/1/2017
-
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis
4/21/2017
-
Valeant Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call
4/11/2017